InpharmD™





One touch literature search.

So you can spend more time with patients

Ask any clinical question, receive a curated response.

Get Started Free

Trusted by 10,000+ clinical pharmacists.

                           

Play Circle

Learn about InpharmD™ in under 90 seconds

What is InpharmD™?


Literature searching is tedious. InpharmD™ is here to help.

Clinical pharmacists can ask any question, anytime, from anywhere, and we’ll perform a custom literature search.

(And a 32% chance it’s already been asked.)


More than 30 of the world's best health systems hire an InpharmD™ virtual DI pharmacist, yielding:


129,642

Clinical Pharmacist Hours Saved

4x +

ROI

100%

Customer Satisfaction Rate

This is how InpharmD™ transforms LITERATURE.

What's Being Asked...

Is there a lab resource that states what a critical INR value would be for neonates and pediatric patients?
What data is available on the clinical need for UTI prophylaxis? If it is needed, what are recommended agents and dos...
Is there data showing which carbapenems are most safe in patients with a history of seizures?
Class Review of IV Infusions used for treatment/maintenance of Myasthenia gravis: Vyvgart, Vyvgart Hytrulo, Rystiggo,...
What is the recommended dosing strategy and supporting clinical evidence for subcutaneous unfractionated heparin for ...

What would you like to ask InpharmD™?

InpharmD's Answer GPT's Answer

Author:Neil Patel, PharmD, BCPS + InpharmD™ AI LEARN MORE 

There is a lack of consensus on what constitutes a laboratory-defined critical international normalized ratio (INR) for neonates and pediatric patients. Although multiple studies establish age- and population-specific reference intervals, there is no singular critical INR threshold defined for either neonates or children. Neonatal INR values are physiologically higher and change dynamically with gestational and postnatal age, while pediatric INR values remain modestly higher than adult norms ...

Available evidence consistently shows that age- and context-specific reference intervals for international normalized ratio (INR) exist in neonates, but a laboratory critical INR threshold remains undefined. In healthy term neonates, an investigation utilizing point-of-care INR testing (CoaguChek XS) demonstrated a narrow reference interval at 4 days of life, with a median INR of 1.10 and a range of 0.90-1.30 after routine vitamin K administration, indicating that modest elevations above adult norms may still be physiologic in this population. Larger population-based data from the Copenhagen Baby Heart Study and COMPARE further confirm that normal neonatal INR values are higher than adult values and vary by gestational age, with reference intervals of approximately 1.1-1.7 in late-preterm/early-term neonates and 1.2-1.8 in full-term neonates, reinforcing that neonatal INR interpretation must be age-stratified rather than based on adult thresholds. [1-4] In contrast to healthy ...

READ MORE→

A search of the published medical literature revealed 0 studies investigating the researchable question:

Is there a lab resource that states what a critical INR value would be for neonates and pediatric patients?

Level of evidence
X - No data  

READ MORE→

[1] Iijima S, Baba T, Ueno D, Ohishi A. International normalized ratio testing with point-of-care coagulometer in healthy term neonates. BMC Pediatr. 2014;14:179. Published 2014 Jul 9. doi:10.1186/1471-2431-14-179
[2] Nielsen ST, Strandkjær N, Juul Rasmussen I, et al. Coagulation parameters in the newborn and infant - the Copenhagen Baby Heart and COMPARE studies. Clin Chem Lab Med. 2021;60(2):261-270. Published 2021 Nov 9. doi:10.1515/cclm-2021-0967
[3] De Rose DU, Maddaloni C, Ronci S, et al. Coagulation profiles and percentiles in neonates with hypoxic-ischemic encephalopathy undergoin...

InpharmD's Answer GPT's Answer

Author:Neil Patel, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Urinary tract infection (UTI) guidelines recommend prophylaxis in patient groups with recurrent cystitis. Antibiotic prophylaxis is suggested to be the most effective strategy, utilizing regimens such as nitrofurantoin (50 mg or 100 mg once daily), fosfomycin trometamol (3 g once a week) or trimethoprim (100 mg once daily. In pregnant patients, suppressive regimens such as nitrofurantoin 100 mg orally daily or cephalexin 250–500 mg orally daily may be considered. In the pediatric population, ...

The 2025 European Association of Urology (EAU) discusses the prophylactic efficacy of various nutraceuticals for preventing recurrent cystitis has been the focus of several research studies. Investigations into probiotics, particularly Lactobacillus spp. administered vaginally and in combination with oral probiotics, show effectiveness in preventing symptomatic cystitis recurrence. However, a systematic review finds lactobacilli alone do not demonstrate superiority over placebo or cranberry monotherapy, highlighting the need for better quality evidence to guide recommendations on administration routes or dosages. Cranberry prophylaxis, particularly with standardized cranberry extract, has been shown to significantly reduce cystitis recurrence in diabetic postmenopausal women and in adult women with recurrent cystitis. Yet, optimal dosing remains unclear, though increased fluid intake with cranberry juice may help reduce cystitis rates. [1] Preliminary evidence has found some supp...

READ MORE→

A search of the published medical literature revealed 0 studies investigating the researchable question:

What data is available on the clinical need for UTI prophylaxis? If it is needed, what are recommended agents and dosing?

READ MORE→

[1] European Association of Urology. EAU Guidelines on Urological Infections. Published March 1, 2025. Accessed Jan 21, 2026]. https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Urological-infections-2025.pdf
[2] Ackerman AL, Bradley M, D’Anci KE, Hickling D, Kim SK, Kirkby E, et al. Updates to Recurrent Uncomplicated Urinary Tract Infections in Women: AUA/CUA/SUFU Guideline (2025). J Urol. Published 2025. doi:10.1097/JU.0000000000004723. Accessed [January 21, 2026].
[3] Urinary Tract Infections in Pregnant Individuals. Obstetrics & Gynecology 142(2):p 435-445...

InpharmD's Answer GPT's Answer

Author:azkaa@inpharmd.com, PharmD, BCPS + InpharmD™ AI LEARN MORE 

The absolute risk of seizures with carbapenems overall appears to be low, with imipenem having the highest propensity. One retrospective study in older adults significantly correlated carbapenem-induced seizure in patients with a history of seizures; however, this study also found imipenem to have the lowest incidence of seizures (Table 1). Available data suggest benzodiazepines as an option for carbapenem-associated seizures.

Carbapenems’ known ability to cause seizures may be directly tied to their beta-lactam ring structure, which is similar enough to gamma-aminobutyric acid (GABA) to antagonize central GABA receptors. Individual carbapenems and seizure activity data are sparse. A literature search of the MEDLINE (1966-May 2010), EMBASE (1974-May 2010), and International Pharmaceutical Abstracts (1970-May 2010) databases was conducted to determine the existing evidence on the connection between carbapenem agents and seizure activity. There have been multiple instances of seizures linked to imipenem-cilastatin, with seizure rates ranging from 3 to 33%. The seizure rate for meropenem, doripenem, and ertapenem is stated to be less than 1%. However, as their usage grows and expands into new patient populations, the rate of seizures associated with these drugs may rise. High-dose therapy also increases the chance of seizure activity, especially in patients with renal impairment, prior central nervous system...

READ MORE→

A search of the published medical literature revealed 2 studies investigating the researchable question:

What is the comparative safety profile of individual carbapenems, specifically meropenem, imipenem, and doripenem, in patients with a history of seizures?

Level of evidence
C - Multiple studies with limitations or conflicting results  

READ MORE→

[1] Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy. 2011;31(4):408-423. doi:10.1592/phco.31.4.408
[2] Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother. 2014;69(8):2043-2055. doi:10.1093/jac/dku1111
[3] Wanleenuwat P, Suntharampillai N, Iwanowski P. Antibiotic-induced epileptic seizures: mechanisms of action and clinical considerations. Seizure. 2020;81:167-174. doi:10...

InpharmD's Answer GPT's Answer

Author:Naveed Aijaz, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Attached is the requested review of Myasthenia gravis injectable agents, with additional agents added as a bonus. Thank you!

A search of the published medical literature revealed 0 studies investigating the researchable question:

Class Review of IV Infusions used for treatment/maintenance of Myasthenia gravis: Vyvgart, Vyvgart Hytrulo, Rystiggo, Imaavy and Uplinza

READ MORE→

InpharmD's Answer GPT's Answer

Author:AJ Carvajal, PharmD, BCPS + InpharmD™ AI LEARN MORE 

Although an ideal dosing regimen for VTE prophylaxis in obese patients has not been established, limited data collected from guidelines and review articles suggest using unfractionated heparin (UFH) 7,500 units Q8H in patients with a body mass index ≥40 kg/m2. Previous recommendations had utilized 5,000 units UFH Q8H for VTE prophylaxis in critically ill obese patients; however, in more extreme obesity (BMI ≥ 50 kg/m2), 7,500 units of UFH Q8H may be considered. While much of the literature s...

The 2012 American College of Chest Physicians (ACCP) guidelines for the prevention of VTE in nonsurgical patients recommend for acutely ill hospitalized medical patients who are at increased risk of thrombosis to be on anticoagulant thromboprophylaxis with low-molecular-weight heparin (LMWH), low-dose unfractionated heparin (LDUH) twice daily, LDUH three times daily, or fondaparinux. The recommended prophylaxis dose for unfractionated heparin is 5000 units twice or three times daily; there is no distinct recommendation on doses for patients who are obese. [1,2] A 2016 review in response to the 2012 ACCP guidelines examined different chemical prophylaxis to prevent venous thromboembolism in morbidly obese patients (BMI > 40 kg/m2) since the specific patient population is not defined in previous ACCP guidelines. The paper concludes that if unfractionated heparin (UFH) is used, then the recommended dose is 7,500 units SQ TID (increased from 5,000 units BID to TID). The review advise...

READ MORE→

A search of the published medical literature revealed 9 studies investigating the researchable question:

What is the recommended dosing strategy and supporting clinical evidence for subcutaneous unfractionated heparin for VTE prophylaxis in patients with obesity?

Level of evidence
B - One high-quality study or multiple studies with limitations  

READ MORE→

[1] Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published correction appears in Chest. 2012 May;141(5):1369. Dosage error in article text] [published correction appears in Chest. 2013 Aug;144(2):721. Dosage error in article text]. Chest. 2012;141(2 Suppl):e24S-e43S. doi:10.1378/chest.11-2291
[2] Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9t...

Why choose InpharmD™?

Find answers, not documents.

Before InpharmD™


BeforeTime
Your team spends hours per week cobbling together literature from different studies, many behind paywalls, leaving little time for action.
BeforeTime
TI opportunities are discovered (or presented by third parties) months after the fact, resulting in costly missed savings.
BeforeTime
Decisions may be made without a complete picture, or pushed out while gathering consensus.

After InpharmD™


BeforeTime
InpharmD™ delivers customized, actionable drug information in real time, so you can focus on execution.
BeforeTime
Your team stays informed immediately when new data emerges or prices change, and you’ll always be the first to know when any changes impact your formulary.
BeforeTime
With InpharmD™, your team can make faster, more informed decisions and move forward with confidence.

What Clinical Pharmacists Are Saying...


     

Assists in our research and is a great way or us to get an answer to a medical question without spending an average of 2 hours researching UptoDate or PubMed ourselves.


  Jordan C., PharmD, New Jersey

     

Huge time saver with thorough responses.


  Jane D., PharmD, Georgia

     

I’d never heard of a DI pharmacist before, now I have one. In. My. Pocket. Amazing!


     

Holy Shhh. Cow! Holy Cow! These summaries are beautiful.


  Jane D., PharmD, Georgia

     

I just want to say: This is such a brilliant idea! You people are genius.


     

OH MY GOD WHERE HAVE YOU BEEN ALL MY LIFE!


     

I can’t tell you how much time I spend literature searching. And how I CANNOT STAND PAYWALLS. THIS IS UNBELIEVABLE!! (covers face for sec) thank you, thank you, thank you!


     

So they’re basically connecting academic researchers with front line providers and then automating everything. It’s simply brilliant.


     

The clinical pharmacist was our secret weapon anyway. (Smiles wryly) This pharmacist AI seems superhuman. I’m just blown away, honestly. (Looks at camera somberly.)


     

It’s an ENTIRE DI DEPARTMENT, that lives in Epic. Give me a second. I’m just having a hard time wrapping my head around that.


     

Sorry just give me a second, my mind is blown.


     

Stop reading and just download the app already! I’ve tried all of them. This is by far the most advanced, best-in-class.


What would you like to ask InpharmD™?

Sign up for a free trial & start right away.

Get Started Free